Skip to main
GUTS
GUTS logo

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is positioned positively within the metabolic therapeutics sector, particularly as prescriptions for GLP-1 drugs to treat obesity have surged by 587% from 2019 to 2024, indicating increasing market demand. The company’s focus on developing durable, disease-modifying therapies that target the root causes of type 2 diabetes and obesity aligns with emerging trends in healthcare that favor effective long-term solutions over symptomatic management. Additionally, Fractyl Health's anticipated advances in manufacturing capabilities and the promising results from their GLP-1 PGTx program, which show greater improvements in blood glucose and weight control compared to existing treatments, further enhance the company's growth potential.

Bears say

Fractyl Health Inc. exhibits a negative financial outlook primarily due to concerns surrounding its significant cash burn, which may worsen with the expansion of development and commercial programs. Although there were reductions in HbA1c and fat mass measurements, the underlying challenge remains with type 2 diabetes patients facing progressive β-cell dysfunction, necessitating ongoing therapeutic interventions and limiting market potential. Moreover, while potential collaborations could provide milestone revenue, the instability of cash flow and reliance on external partnerships could pose substantial risks to the company's financial health and sustainability.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.